GSK stock declines as sellers take control over recent sessions

Traders Union
All News
Financial News
GSK slides 1.70% to GBX1,993.50 today

Highlights

GSK delivered first-quarter 2026 core operating profit growth of 10% to £2.65 billion, surpassing expectations with strong performance in respiratory, HIV, and oncology drugs.
Shingrix vaccine sales rose 20% to £1.0 billion, while Arexvy RSV sales fell seasonally by 18%; full-year 2026 guidance and a 15p dividend were reaffirmed amid ongoing price pressure.
Shares trade below short-term averages under persistent selling but exhibit several oversold technical signals, positioning for a likely rebound into the GBX 1,940–2,080 range over the next week.

Profit beat and vaccine results counter selling pressure

GSK reported first-quarter 2026 profit that exceeded analyst expectations, with core operating profit rising 10% at constant exchange rates to £2.65 billion and core earnings per share reaching 46.5 pence. Strong sales in the respiratory, HIV, and cancer medicines segments contributed to this result. Shingrix vaccine sales climbed 20% to £1.0 billion, while Arexvy RSV vaccine sales saw an expected seasonal decline of 18%. The company reaffirmed its full-year 2026 guidance and declared a first-quarter dividend of 15 pence per share, though price action has remained under broader selling pressure.

Oversold signals as technical support and volatility converge

The GBX 1,993.50 quote is positioned below the SMA-20 at GBX 2,107.15 and SMA-50 at GBX 2,100.26, with the SMA-200 at GBX 1,781.39 providing deeper support. The Ichimoku Kijun level for D1 is at GBX 2,054.14, acting as near-term resistance. Momentum readings are neutral on both the MACD and ADX indicators, indicating a pause in trend strength. Oscillators including RSI (41.08 D1), CCI (-145.02 D1), and Stoch RSI (9.82 D1) are in oversold territory, and the BBP indicator registers a negative value consistent with short-term seller dominance. The asset is trading near the session low within a volatile daily range of GBX 1,955.71 – 2,048.00. While most momentum signals confirm prevailing weakness, several oscillators highlight oversold conditions and signal risk of a short-term technical rebound.

Consolidation favored as breakout risks frame outlook

For the next five trading days, GSK is expected to move within a volatility band of GBX 1,940 to GBX 2,080, representing a typical fluctuation range from current levels. The most probable scenario is a period of consolidation within this corridor. Should the price breach immediate resistance above GBX 2,054, a move toward higher levels may follow, while a drop below GBX 1,940 could trigger increased selling if support fails.

Anton Kharitonov, expert at Traders Union, sees GSK under pressure despite robust first-quarter numbers and outperformance in several key medicine segments. Technically, the share price remains weak below important short-term averages, with indicators showing both prevailing weakness and deeply oversold signals. He believes the stock is likely to consolidate within a volatile band, but a break of either resistance at GBX 2,054 or support at GBX 1,940 will define the next move. "Until GBX 2,054 is convincingly reclaimed, I remain cautious and avoid upside bets here."

In a recent review, analysts noted that GSK shares remained under short- and medium-term selling pressure despite underlying support from its long-term trends and continued advances in its vaccine portfolio. The latest earnings beat and signs of technical oversold conditions add support for a potential short-term rebound, making GBX 2,054 a key resistance level to watch for any meaningful shift in direction.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.